B-ALL
Clinical trials for B-ALL explained in plain language.
Never miss a new study
Get alerted when new B-ALL trials appear
Sign up with your email to follow new studies for B-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new CAR-T cell therapy called ThisCART19A in 10 adults with relapsed or hard-to-treat B-cell leukemia. The goal was to check safety and see how well the treatment worked. Participants received a single infusion of their own engineered immune cells,…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
Engineered immune cells show promise against tough childhood cancers
Disease control CompletedThis study tested a new treatment for children and young adults (ages 1-39) with B-cell leukemia or lymphoma that did not respond to standard therapy. The treatment involved taking a patient's own white blood cells, modifying them in a lab to target the CD22 protein on cancer cel…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Engineered immune cells take aim at tough blood cancers
Disease control CompletedThis study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from patients' own blood cells and safely given to adults with hard-to-treat B-cell leukemia or lymphoma. The main goals were to see if the cells could be produced successfully and…
Matched conditions: B-ALL
Phase: PHASE1 • Sponsor: Matthew Frank • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…
Matched conditions: B-ALL
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC